Being more realistic about the public health impact of genomic medicine.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Risk Prediction Models for Colorectal Cancer: A Systematic Review.Cancer prevention research (Philadelphia, Pa.) · 2016
   Pooled it
2. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.Nature medicine · 2022
   Trial
3. Evaluating Approaches for Communication About Genomic Influences on Body Weight.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2015
   Trial
4. Governing Personalized Health: A Scoping Review.Frontiers in genetics · 2021
   Article
5. Molecular and genomic sciences in health: apply the established rules of evidence.International journal of public health · 2016
   Article
6. Pragmatic medicine in solid cancer: a translational alternative to precision medicine.OncoTargets and therapy · 2016
   Article
7. Genetic and Environmental Interplay in Adolescent Substance Use Disorders.Current addiction reports · 2015
   Article
8. Perceptions of genetic testing and genomic medicine among drug users.The International journal on drug policy · 2015
   Article
9. Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Addiction science & clinical practice · 2014
   Review
10. Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate.PLoS biology · 2013
    Article
11. Application of PHEL - 'Public Health Epidemiological Logic' of Public Health Intervention and Public Health Impact.International journal of preventive medicine · 2013
    Article
12. Enhancing Children against Unhealthy Behaviors-An Ethical and Policy Assessment of Using a Nicotine Vaccine.Public health ethics · 2013
    Article
13. Do we know enough? A scientific and ethical analysis of the basis for genetic-based personalized nutrition.Genes & nutrition · 2013
    Article
14. Harm, hype and evidence: ELSI research and policy guidance.Genome medicine · 2013
    Article
15. Beyond base pairs to bedside: a population perspective on how genomics can improve health.American journal of public health · 2012
    Article
16. Personalized medicine: caught between hope, hype and the real world.Clinics (Sao Paulo, Brazil) · 2012
    Review
17. Comparison of family history and SNPs for predicting risk of complex disease.PLoS genetics · 2012
    Article
18. Biobanking and public health: is a human rights approach the tie that binds?Human genetics · 2011
    Article
19. Direct-to-consumer testing: if consumers are not anxious, why are policymakers?Human genetics · 2011
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as